Heard on the Street: Novo Nordisk and Pfizer are showing some desperation in their gloves-off fight for the obesity-drug assets of Metsera
NegativeHealth

Novo Nordisk and Pfizer are in a fierce and desperate competition for the obesity-drug assets of Metsera, highlighting the intense pressure in the pharmaceutical industry to secure effective treatments for obesity. This battle not only reflects the high stakes involved in the obesity market but also raises concerns about the lengths companies will go to in order to gain an edge, potentially impacting innovation and pricing in the sector.
— Curated by the World Pulse Now AI Editorial System


